BTK
BTK (Bruton's tyrosine kinase) inhibitors are compounds that specifically target and inhibit BTK, a crucial enzyme involved in B-cell receptor signaling and the regulation of angiogenesis. BTK plays a significant role in the proliferation and survival of cancer cells, particularly in hematological malignancies. By inhibiting BTK, these compounds can disrupt angiogenesis and tumor growth, making them valuable in cancer therapy. At CymitQuimica, we offer a range of high-quality BTK inhibitors to support your research in oncology, immunology, and angiogenesis.
Found 166 products of "BTK"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
BLK-IN-2
CAS:BLK-IN-2为一种高效、选择性且不可逆的B-淋巴酪氨酸激酶(BLK)抑制剂，具有5.9 nM的IC50值。该化合物亦能抑制BTK，其IC50值为202.0 nM。BLK-IN-2在多种淋巴瘤细胞中展现出显著的抗增殖作用。
Formula:C39H41N9O3Color and Shape:SolidMolecular weight:683.8JAK3/BTK-IN-6
CAS:JAK3/BTK-IN-6: potent BTK (0.6 nM) & JAK3 (0.4 nM) inhibitor, stable in human liver, for blood/immune research.Formula:C21H17BF3N5O3Color and Shape:SolidMolecular weight:455.2BTK-IN-22
CAS:BTK-IN-22 is a selective BTK inhibitor with IC50 of 0.9 nM; also targets BLX, BMX (IC50s: 1.4, 1.2 nM); better selectivity than Ibrutinib.Formula:C26H26N6O2Color and Shape:SolidMolecular weight:454.52GDC-0834 Racemate
CAS:GDC-0834 Racemate is the racemate form of GDC-0834, which is an effective and selective BTK inhibitorFormula:C33H36N6O3SColor and Shape:SolidMolecular weight:596.74HZ-A-005
CAS:HZ-A-005 is a selective, potent, covalent inhibitor of Bruton's tyrosine kinase (BTK). HZ-A-005 significantly inhibits tumour growth in a xenograft mouse model.Formula:C25H23ClN6O2Color and Shape:SolidMolecular weight:474.94BI-1622
CAS:BI-1622, an oral HER2 inhibitor, IC50: 7 nM, >25x selectivity over EGFR, shows effective in vivo antitumor activity.Formula:C26H24N10O2Color and Shape:SolidMolecular weight:508.53BLK degrader 1
CAS:BLK degrader 1 is a BLK degrader with anticancer activity for cancer research.Formula:C32H25F3N6O2Purity:99.22% - 99.24%Color and Shape:SolidMolecular weight:582.58JS25
CAS:JS25, a selective BTK inhibitor, inactivates it with a 5.8 nM IC50, halts cancer cell growth, induces death, and aids against lymphoma.Formula:C29H24N4O4SColor and Shape:SolidMolecular weight:524.59BTK-IN-23
CAS:BTK-IN-23: BTK inhibitor, IC50=12.8 nM; also blocks BLX (35.6 nM), BMX (5.7 nM); better selectivity than Ibrutinib.Formula:C27H28N6O2Color and Shape:SolidMolecular weight:468.55JNJ-64264681
CAS:JNJ-64264681 is a potent, orally active, selective, and irreversible covalent inhibitor of Bruton's tyrosine kinase (BTK).Formula:C27H30N6O3SPurity:98%Color and Shape:SolidMolecular weight:518.63Ibrutinib-MPEA
CAS:Ibrutinib-MPEA is ibrutinib derivative. Ibrutinib is a covalent and irreversible BTK inhibitor that has been used to treat hematological malignancies.Formula:C32H39N9O2Color and Shape:SolidMolecular weight:581.71CGI560
CAS:CGI560 is a potent BTK inhibitor with IC50 = 400 nM for BTK.Formula:C29H27N5OColor and Shape:SolidMolecular weight:461.56SB-633825
CAS:SB-633825 can inhibit cancer cell growth and angiogenesis.Formula:C28H25N3O3SPurity:98%Color and Shape:SolidMolecular weight:483.58Sunvozertinib
CAS:Sunvozertinib (DZD9008) is a potent ErbBs and BTK inhibitor, with inhibitory effects on EGFR, Her2.Cost-effective and quality-assured.Formula:C29H35ClFN7O3Purity:98.11% - 99.63%Color and Shape:SolidMolecular weight:584.08Ref: TM-T64124
1mg34.00€5mg60.00€10mg85.00€25mg124.00€50mg200.00€100mg353.00€500mg1,314.00€1mL*10mM (DMSO)150.00€Tilfrinib
CAS:Tilfrinib is an effective and selective inhibitor of breast tumor kinase(Brk, IC50 = 3.15 nM) which displays anti-proliferative and anti-tumor activities.Formula:C17H13N3OPurity:99.54%Color and Shape:SolidMolecular weight:275.3Ref: TM-T17098
1mg43.00€2mg56.00€5mg93.00€10mg130.00€25mg243.00€50mg439.00€100mg645.00€500mg1,333.00€1mL*10mM (DMSO)93.00€(±)-Zanubrutinib
CAS:(±)-Zanubrutinib ((±)-BGB-3111) is a potent and orally available Bruton's tyrosine kinase (Btk) inhibitor that demonstrates superior oral bioavailability,Formula:C27H29N5O3Purity:99.09%Color and Shape:SolidMolecular weight:471.55Ref: TM-TQ0039
1mg47.00€5mg92.00€10mg145.00€25mg256.00€50mg409.00€100mg587.00€500mg1,215.00€1mL*10mM (DMSO)101.00€CHMFL-EGFR-202
CAS:CHMFL-EGFR-202 is a potent, irreversible inhibitor of EGFR mutant kinase (IC50s: 5.3 nM and 8.3 nM for drug-resistant mutant EGFR T790M and WT EGFR kinases).Formula:C25H24ClN7O2Purity:99.66%Color and Shape:SolidMolecular weight:489.96Ref: TM-T10802
1mg109.00€2mg163.00€5mg241.00€10mg355.00€25mg532.00€50mg745.00€100mg1,018.00€1mL*10mM (DMSO)289.00€Larotinib
CAS:Larotinib is an orally active, potent, and broad-spectrum tyrosine kinase inhibitor (TKI) with an IC50 of 0.6 nM for EGFR.Formula:C24H26ClFN4O4Purity:99.73%Color and Shape:SolidMolecular weight:488.94NX-2127
CAS:NX-2127 (ETX2514 Triethylamine) is an orally active BTK inhibitor that induces degradation of mutant BTKC481S in cells.NX-2127 has potent antiproliferativeFormula:C39H45N9O5Purity:99.07%Color and Shape:SolidMolecular weight:719.83(R)-Zanubrutinib
CAS:(R)-Zanubrutinib ((R)-BGB-3111) is a selective inhibitor of Bruton tyrosine kinase (BTK).Formula:C27H29N5O3Purity:99.55%Color and Shape:SolidMolecular weight:471.55Ref: TM-T13447
1mg37.00€5mg80.00€10mg133.00€25mg215.00€50mg323.00€100mg442.00€200mg615.00€1mL*10mM (DMSO)85.00€Edralbrutinib
CAS:Edralbrutinib (TG-1701) is a potent BTK inhibitor with anticancer activity and is used in the treatment of tumors, immune system disorders, and blood andFormula:C26H21F2N5O3Purity:99.41%Color and Shape:SolidMolecular weight:489.47BTK-IN-11
CAS:BTK-IN-11: potent BTK inhibitor; may research autoimmune, inflammatory diseases, cancer. (Patent WO2022063101A1, Z2)Formula:C26H22ClN5O3Color and Shape:SolidMolecular weight:487.94BMX-IN-1
CAS:BMX-IN-1 (BMX kinase inhibitor) is a selective inhibitor of bone marrow tyrosine kinase on chromosome X (BMX, IC50 = 8 nM) and the related Bruton’s tyrosineFormula:C29H24N4O4SPurity:98.38%Color and Shape:SolidMolecular weight:524.59DDa-1
CAS:DDa-1 is a potent (kinase degrader) [1].Formula:C60H77Cl2N13O3SColor and Shape:SoildMolecular weight:1131.31BTK-IN-17
BTK-IN-17: selective, oral BTK inhibitor, IC50=13.7 nM, reduces p-BTK Y223/p-PLCγ2 Y1217, anti-inflammatory.Formula:C26H23N7O2Color and Shape:SolidMolecular weight:465.51BTK-IN-18
CAS:BTK-IN-18 is a potent, reversible inhibitor of Bruton's tyrosine kinase (BTK) with an inhibitory concentration (IC50) of 0.002 µM.Formula:C20H22Cl2N6OColor and Shape:SolidMolecular weight:433.33PF-303
CAS:PF-303, a reversible covalent BTK inhibitor, shows potential for cancer and autoimmune therapy.Formula:C22H21ClN6O2Color and Shape:SolidMolecular weight:436.89(Rac)-PF-06250112
CAS:(Rac)-PF-0625011 is a racemic mix, orally active, selective BTK inhibitor, also targeting BMX and TEC kinases.Formula:C22H20F2N6O2Purity:98%Color and Shape:SolidMolecular weight:438.43BTK-IN-19
CAS:BTK-IN-19 is a reversible BTK inhibitor with an IC 50 of <0.001 μM .Formula:C21H22Cl2N6OColor and Shape:SolidMolecular weight:445.35Cinsebrutinib
CAS:Cinsebrutinib, a Bruton's tyrosine kinase inhibitor, holds potential for research in cancer treatment.Formula:C22H26FN3O2Purity:98%Color and Shape:SolidMolecular weight:383.46BTK inhibitor 13
CAS:BTK inhibitor 13 (compound 8) is an effective and selective BTK inhibitor(IC50: 1.2 nM).Formula:C29H26FN5O3Purity:98%Color and Shape:SolidMolecular weight:511.55BTK inhibitor 20
CAS:BTK inhibitor 20 is a potent BTK inhibitor with an IC 50 of 8 nM .Formula:C37H42N8O4Color and Shape:SolidMolecular weight:662.78PF-06250112
CAS:PF-06250112 is an effective and highly selective BTK inhibitor (IC50: 0.5 nM.Formula:C22H20F2N6O2Purity:98%Color and Shape:SolidMolecular weight:438.43Pirtobrutinib
CAS:Pirtobrutinib: a selective, non-covalent BTK inhibitor effective against BTK C481 mutations, causing tumor regression in lymphoma models.Formula:C22H21F4N5O3Purity:99.76% - 99.94%Color and Shape:SolidMolecular weight:479.43Ref: TM-T36287
1mg37.00€5mg79.00€10mg126.00€25mg283.00€50mg434.00€100mg638.00€500mg1,359.00€1mL*10mM (DMSO)84.00€BTK inhibitor 1
CAS:BTK inhibitor 1 (Compound 27) is a BTK inhibitor (IC50: 0.11 nM) with an inhibitory effect on B-cell activation in hWB with an IC50 of 2 nM.
Formula:C24H23FN8O2Purity:98.24% - 98.91%Color and Shape:SolidMolecular weight:474.49BGB-8035
CAS:BGB-8035 is a BTK inhibitor with antitumor activity that inhibits BTK, TEC, and EGFR.BGB-8035 is used in the study of tumors and autoimmune diseases.Formula:C24H31N5O4Purity:96.74%Color and Shape:SolidMolecular weight:453.53BMS-935177
CAS:BMS-935177 is a reversible BTK inhibitor with IC50 value of 3 nM.Formula:C31H26N4O3Purity:99.89%Color and Shape:SolidMolecular weight:502.56TAK-020
CAS:TAK-020 is a potent covalent inhibitor of Btk with potential antitumor activity for the study of rheumatoid arthritis and immune-related diseases.Formula:C18H17N5O3Purity:98.66%Color and Shape:SolidMolecular weight:351.36Ref: TM-T9529
1mg138.00€5mg334.00€10mg597.00€25mg1,234.00€50mg1,908.00€100mg2,952.00€1mL*10mM (DMSO)358.00€BTK-IN-6
BTK-IN-6, a potent BTK inhibitor, may treat immune, cardiac, cancer, viral, inflammatory, metabolic, and neurological disorders.Formula:C23H22FN5O3Color and Shape:SolidMolecular weight:435.45BTK inhibitor 18
BTK inhibitor 18 is a selective, potent, covalent, orally active Btk inhibitor (IC50: 142 nM) that exhibits anti-inflammatory effects.Formula:C29H25N5O4S2Color and Shape:SolidMolecular weight:571.67GNE-431
CAS:GNE-431: potent, selective noncovalent Btk inhibitor, IC50=3.2 nM; effective against C481R, T474I, T474M mutants, may counter ibrutinib resistance.Formula:C30H32N10O2Color and Shape:SolidMolecular weight:564.64JAK3/BTK-IN-7
CAS:JAK3/BTK-IN-7 (XL-12), characterized as a JAK3/BTK inhibitor, exhibits IC 50 values of 2 nM and 14 nM for JAK3 and BTK respectively. This compound demonstrates anti-inflammatory properties and is applicable in research related to rheumatoid arthritis [1].Formula:C29H30N8O4Color and Shape:SolidMolecular weight:554.6JAK3/BTK-IN-3
CAS:JAK3/BTK-IN-3: strong dual JAK3/BTK suppressor, promising for autoimmune disease research.Formula:C22H28N8OColor and Shape:SolidMolecular weight:420.51Brefeldin A 4-O-nicotinate
CAS:Brefeldin A 4-O-nicotinate (CHNQD-01228) is a dual inhibitor of Arf1 and BMX proteins with an IC50 value of 0.22 μM for T24 cell proliferation. It also suppresses T24 cell migration and colony formation in a dose-dependent manner, induces G1 phase arrest, and triggers apoptosis. By targeting BMX proteins, it inhibits the AKT/p-AKT and STAT3/p-STAT3 signaling pathways, while also inhibiting Arf1 proteins to eliminate bladder cancer stem cells and activate antitumor immunity, thus exhibiting anticancer activity. Brefeldin A 4-O-nicotinate is applicable in research related to bladder cancer.Formula:C22H27NO5Color and Shape:SolidMolecular weight:385.453BTK-IN-16
CAS:BTK-IN-16 is a potential inhibitor of wild-type BTK and C481S mutants.BTK-IN-16 can be used to study various autoimmune diseases and cancers caused by BTK.Formula:C15H14N4O2Purity:99.04%Color and Shape:SoildMolecular weight:282.3BIIB129
CAS:BIIB129 is a selective and brain-penetrant BTK covalent inhibitor used to study B-cell proliferation-related diseases.Formula:C19H22N6O2Purity:98.56%Color and Shape:SolidMolecular weight:366.42JAK3/BTK-IN-4
CAS:JAK3/BTK-IN-4, a dual inhibitor for JAK3/BTK, shows synergy in autoimmune disease treatment. (Patent WO2021147953A1, compound 003)Formula:C21H25ClN8OColor and Shape:SolidMolecular weight:440.93WS-11
CAS:WS-11 is a non-covalent reversible inhibitor of BTK, with IC50 values of 3.9 nM for the wild-type and 2.2 nM for the C481S mutant BTK. In addition to strong hydrogen bonding, WS-11 also forms robust π-π interactions with PHE540, and p-π interactions with LYS430 within the active pocket.Formula:C26H22FN9O2Color and Shape:SolidMolecular weight:511.51BTK-IN-38
CAS:BTK-IN-38 (Example 125) is an efficacious inhibitor of BTK. It effectively suppresses the proliferation of DOHH2 and BT474 cells, with IC50 values of 114 nM and 340 nM, respectively.Formula:C27H26F2N4O2Color and Shape:SolidMolecular weight:476.52BMS-986143
CAS:BMS-986143: oral BTK inhibitor, IC50=0.26 nM, potential for autoimmune research, also targets TEC, BLK, BMX, TXK, YES1, ITK.Formula:C31H24Cl2N4O4Color and Shape:SolidMolecular weight:587.45UBX-382
CAS:UBX-382 is an orally administered proteolysis-targeting chimera (PROTAC) designed to target BTK and disrupt B-cell receptor signaling. It demonstrates enhanced degradation of both wild-type and mutant BTK proteins, exhibiting anti-cancer effects in murine xenograft models using TMD-8 cells [1].Formula:C42H44N10O4Color and Shape:SolidMolecular weight:752.86BTK-IN-15
BTK-IN-15: Oral BTK inhibitor, IC50 0.7 nM, induces cancer cell apoptosis, selective with anti-tumor effects.Formula:C28H24FN5O2Color and Shape:SolidMolecular weight:481.52BTK-IN-32
CAS:BTK-IN-32 (compound C2) acts as a potent BTK inhibitor. Unlike isolated kinase domains, this compound activates full-length BTK as well as its smaller multidomain fragments [1].Formula:C35H35ClN4O3SColor and Shape:SolidMolecular weight:627.2RET-IN-14
CAS:RET-IN-14 inhibits RET (IC50: <0.51-9.3 nM) & BTK (C481S) (IC50: 9.2-15 nM), promising for tumor research.Formula:C24H23FN8O4Color and Shape:SolidMolecular weight:506.49G-744
CAS:G-744 is a selective and orally active inhibitor of Btk (IC50: 2 nM).Formula:C29H29N5O3SPurity:98%Color and Shape:SolidMolecular weight:527.64TQ-3959
CAS:TQ-3959 is an orally active BTKPROTAC degrader, with a DC50 of 14.6 nM. It exhibits antiproliferative activity against both wild-type BTK and BTK C481S mutant cell lines. TQ-3959 demonstrates tumor growth inhibition in female NOD-SCID mice with TMD-8 xenografts. This compound is applicable in the study of B-cell malignancies, such as lymphoma.Formula:C40H47N11O5Color and Shape:SolidMolecular weight:761.87(Rac)-Ibrutinib alkyne
CAS:(Rac)-Ibrutinib alkyne (Compound 8) is a Btk inhibitor with an IC50 of 0.72 nM. This compound effectively inhibits B cell receptor signaling functions, with an IC50 of 9 nM for calcium flux inhibition in Ramos cells. (Rac)-Ibrutinib alkyne is applicable in research on diseases such as rheumatoid arthritis.Formula:C25H22N6O2Color and Shape:SolidMolecular weight:438.48BTK-IN-8
BTK-IN-8: potent, selective covalent BTK inhibitor; IC50=0.22 nM, Kd=0.91 nM; effective in blood CD69 cells (IC50=0.029 μM).Formula:C26H36N6O3Color and Shape:SolidMolecular weight:480.6BTK-IN-34
CAS:BTK-IN-34 (compound 9h) functions as a selective BTK inhibitor, exhibiting antiproliferative effects in RAMOS cells by specifically targeting pBTK (Tyr223) while sparing upstream proteins such as Lyn and Syk in the BCR signaling pathway [1].Formula:C22H29N3O4SColor and Shape:SolidMolecular weight:431.55HDHD4-IN-1
CAS:HDHD4-IN-1 (compound 3) is an inhibitor of N-acetylneuraminate-9-phosphate phosphatase (HDHD4) with an IC50 value of 11 μM. It is utilized in the research of neurological disorders.Formula:C12H22NO11PColor and Shape:SolidMolecular weight:387.28BTK-IN-10
CAS:BTK-IN-10 is a potent inhibitor of BTK, acting on wild-type BTK (IC50<5 nM) or mutant BTK (C481S) (IC50<5 nM).Formula:C25H24F2N4O2Color and Shape:SolidMolecular weight:450.48Ibrutinib Racemate
CAS:Ibrutinib is a selective, irreversible Btk inhibitor (IC50: 0.5 nM). Ibrutinib Racemate is the racemate of Ibrutinib.Formula:C25H24N6O2Purity:98%Color and Shape:SolidMolecular weight:440.5Dihydrodiol-Ibrutinib
CAS:PCI 45227 is an active metabolite of the Bruton's tyrosine kinase inhibitor ibrutinib .1PCI 45227 is formed from ibrutinib by the cytochrome P450 (CYP) isoform CYP3A. 1.Veeraraghavan, S., Viswanadha, S., Thappali, S., et al.Simultaneous quantification of lenalidomide, ibrutinib and its active metabolite PCI-45227 in rat plasma by LC-MS/MS: Application to a pharmacokinetic studyJ. Pharm. Biomed. Anal.107151-158(2015)Formula:C25H26N6O4Color and Shape:SolidMolecular weight:474.521JDB175
CAS:JDB175, a selective BTK inhibitor with oral bioavailability, demonstrates excellent penetration through the blood-brain barrier.
Formula:C26H21F3N4O2Purity:98%Color and Shape:SolidMolecular weight:478.47BTK-IN-25
CAS:BTK-IN-25 (compound 71) is a potent BTK inhibitor, demonstrating an IC50 of 0.77 nM against BTK(C481S) and achieving an IC50 of 1 nM in DOHH2 cells [1].
Formula:C28H27F2N3O5Purity:98%Color and Shape:SolidMolecular weight:523.53BTK-IN-27
CAS:BTK-IN-27 (example 8), a potent BTK inhibitor with an IC50 of 0.2 nM, demonstrates anti-proliferative effects in TMD8 cells with an IC50 of less than 5 nM.
Formula:C31H35N7O2Purity:98%Color and Shape:SolidMolecular weight:537.66
